Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease With 3 Years of Treatment: Results From the FORTIFY Open-Label Long-Term Extension

被引：0

作者：

Ferrante, M. ^{[1
]}

Panaccione, R. ^{[2
]}

Colombel, J. F. ^{[3
]}

Dubinsky, M. C. ^{[4
]}

Hisamatsu, T. ^{[5
]}

Lindsay, J. O. ^{[6
]}

Song, A. ^{[7
]}

Yao, Y. ^{[8
]}

Zhang, Y. ^{[8
]}

Zambrano, J. ^{[9
]}

Aponte, F. ^{[10
]}

Duan, W. R. ^{[11
]}

D'Haens, G. ^{[12
]}

机构：

[1] Katholieke Univ Leuven, Dept Gastroenterol & Hepatol, Univ Hosp Leuven, Leuven, Belgium

[2] Univ Calgary, Div Gastroenterol & Hepatol, Inflammatory Bowel Dis Unit, Calgary, AB, Canada

[3] Icahn Sch Med Mt Sinai, Dept Med, Henry D Janowitz Div Gastroenterol, New York, NY USA

[4] Icahn Sch Med Mt Sinai, Susan & Leonard Feinstein IBD Ctr, New York, NY USA

[5] Kyorin Univ, Sch Med, Dept Gastroenterol & Hepatol, Tokyo, Japan

[6] Queen Mary Univ London, Ctr Immunobiol Barts, London Sch Med & Dent, London, England

[7] AbbVie, Clin Dev, N Chicago, IL USA

[8] AbbVie, Stat, N Chicago, IL USA

[9] AbbVie, US Med Affairs, N Chicago, IL USA

[10] AbbVie, Int Med Affairs, N Chicago, IL USA

[11] AbbVie, Med Safety Evaluat, N Chicago, IL USA

[12] Univ Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam UMC, Amsterdam, Netherlands

来源：

JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷

关键词：

D O I：

10.1093/ecco-jcc/jjae190.0055

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP016

引用

页码：i109 / i111

页数：3

共 50 条

[1] Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension
Ferrante, M.
Panaccione, R.
Colombel, J. F.
Dubinsky, M.
Hisamatsu, T.
Lindsay, J. O.
Song, A.
Neimark, E.
Zhang, Y.
Kligys, K.
Crowley, J.
Duan, W. R.
D'Haens, G.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I167 - I169
[2] EFFICACY AND SAFETY UP TO THREE YEARS OF RISANKIZUMAB TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE FORTIFY OPEN-LABEL LONG-TERM EXTENSION
Ferrante, Marc
Panaccione, Remo
Colombel, Jean Frederic
Dubinsky, Marla C.
Hisamatsu, Tadakazu
Lindsay, James O.
Song, Alexandra P.
Neimark, Ezequiel
Zhang, Ying
Kligys, Kristina
Crowley, Jameson
Duan, W. Rachel
D'Haens, Geert
GASTROENTEROLOGY, 2024, 166 (05) : S801 - S802
[3] Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension
Peyrin-Biroulet, L.
Atreya, R.
Danese, S.
Lindsay, J. O.
Chapman, J. C.
Anschutz, T.
Huang, X.
Zambrano, J.
Platt, A.
Joshi, N.
Cross, R. K.
JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1407 - i1409
[4] INTERIM LONG-TERM SAFETY/EFFICACY OF RISANKIZUMAB TREATMENT IN CROHN'S DISEASE PATIENTS FROM THE OPEN-LABEL EXTENSION STUDY
Ferrante, M.
Panes, J.
Baert, F.
Louis, E.
Kaser, A.
Gustafson, D.
Hall, D.
Boecher, W. O.
Herichova, I.
Liao, X.
Wallace, K.
Kalabic, J.
D'Haens, G.
GUT, 2019, 68 : A64 - A64
[5] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study
Ferrante, Marc
Feagan, Brian G.
Panes, Julian
Baert, Filip
Louis, Edouard
Dewit, Olivier
Kaser, Arthur
Duan, W. Rachel
Pang, Yinuo
Lee, Wan-Ju
Gustafson, Dawn
Liao, Xiaomei
Wallace, Kori
Kalabic, Jasmina
D'Haens, Geert R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 (12): : 2001 - 2010
[6] LONG-TERM SAFETY AND EFFICACY OF RISANKIZUMAB TREATMENT IN PATIENTS WITH CROHN'S DISEASE: FINAL RESULTS FROM THE PHASE 2 OPEN-LABEL EXTENSION STUDY
Ferrante, Marc
Feagan, Brian G.
Panes, Julian
Baert, Filip J.
Louis, Edouard
Dewit, Olivier
Kaser, Arthur
Duan, Weijiang
Gustafson, Dawn
Liao, Xiaomei
Wallace, Kori
Kalabic, Jasmina
D'Haens, Geert R.
GASTROENTEROLOGY, 2020, 158 (06) : S1198 - S1198
[7] Long-term safety and efficacy of risankizumab treatment in patients with Crohn's disease: Final results from the Phase 2 open-label extension study
Ferrante, M.
Feagan, B. G.
Panes, J.
Baert, F.
Louis, E.
Dewit, O.
Kaser, A.
Duan, W. R.
Gustafson, D.
Liao, X.
Wallace, K.
Kalabic, J.
D'Haens, G. R.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S024 - S025
[8] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
Feagan, Brian G.
Panes, Julian
Ferrante, Marc
Kaser, Arthur
D'Haens, Geert R.
Sandborn, William J.
Louis, Edouard
Neurath, Markus F.
Franchimont, Denis
Dewit, Olivier
Seidler, Ursula
Kim, Kyung-Jo
Selinger, Christian
Padula, Steven J.
Herichova, Ivona
Robinson, Anne M.
Wallace, Kori
Zhao, Jun
Minocha, Mukul
Othman, Ahmed A.
Soaita, Adina
Visvanathan, Sudha
Hall, David B.
Boecher, Wulf O.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 671 - 680
[9] Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn's Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study
Ferrante, Marc
Feagan, Brian G.
Panes, Julian
Baert, Filip
Louis, Edouard
Dewit, Olivier
Kaser, Arthur
Duan, Weijiang
Gustafson, Dawn
Liao, Xiaomei
Wallace, Kori
Kalabic, Jasmina
D'Haens, Geert R.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S466 - S466
[10] Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Kim A. Papp
Saskia de Vente
Jiewei Zeng
Mary Flack
Byron Padilla
Stephen K. Tyring
Dermatology and Therapy, 2021, 11 : 487 - 497

← 1 2 3 4 5 →